Daniel Joseph Oconnell Sells 12,619 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 12,619 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total value of $20,064.21. Following the transaction, the chief executive officer now owns 667,488 shares of the company’s stock, valued at $1,061,305.92. The trade was a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Friday, January 3rd, Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52.

Acumen Pharmaceuticals Trading Down 4.6 %

Shares of NASDAQ:ABOS opened at $1.65 on Friday. Acumen Pharmaceuticals, Inc. has a 1 year low of $1.53 and a 1 year high of $5.09. The stock’s fifty day moving average price is $1.95 and its 200-day moving average price is $2.46. The company has a market cap of $99.13 million, a P/E ratio of -1.20 and a beta of 0.02. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same quarter in the previous year, the firm earned ($0.24) EPS. Sell-side analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in shares of Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock valued at $44,000 after buying an additional 7,859 shares during the period. JPMorgan Chase & Co. increased its position in Acumen Pharmaceuticals by 252.8% during the third quarter. JPMorgan Chase & Co. now owns 63,066 shares of the company’s stock valued at $156,000 after acquiring an additional 45,189 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Acumen Pharmaceuticals by 5.4% in the third quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company’s stock valued at $8,340,000 after acquiring an additional 181,451 shares during the period. Barclays PLC boosted its position in Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock worth $154,000 after purchasing an additional 40,551 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Acumen Pharmaceuticals by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 864,528 shares of the company’s stock valued at $2,144,000 after purchasing an additional 52,395 shares during the period. Institutional investors own 71.01% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.